Table 2.

Overview of completed and ongoing trials investigating different antithrombotic strategies after TAVR.

Trial	Anti-thrombotic strategy	Target population	Study population	Anticipated completion date	Outcome
Warfarin and antiplatelet therapy vs. warfarin alone for treating patients with atrial fibrillation undergoing TAVR	VKA vs. VKA + single or double APT	Patients with atrial fibrillation	621	Completed	Similar rate of MACE, stroke and death; but significantly higher rate of major or life-threatening bleedings in VKA + APT group (13 months FU)
ARTE NCT01559298	ASA + clopidogrel vs. ASA alone	Patients without need for chronic OAC	222	Completed	No differences in hemodynamics, MACE, TIA, stroke, and death; less major or life-threatening events in ASA alone group (3 months FU)
GALILEO NCT02556203	Rivaroxaban 10 mg + ASA (3 months), followed by rivaroxaban alone vs. DAPT (3 months), followed by ASA alone	Patients without need for chronic OAC	1644	2018	Stopped prematurely because of increased bleeding and mortality in the rivaroxaban group.
AUREA NCT01642134	ASA + clopidogrel vs. VKA	Patients without need for chronic OAC	124	2019	–
POPular–TAVI NCT02247128	ASA + clopidogrel vs. ASA alone, or OAC + clopidogrel vs. OAC alone	All-comers	1,000	2020	–
ATLANTIS NCT02664649	Apixaban vs. standard of care (VKA or SAPT/DAPT)	All-comers	1,510	2020	–
AVATAR NCT02735902	ASA + VKA vs. VKA alone	Patients with underlying indication for chronic OAC	170	2020	–
ENVISAGE-TAVI AF NCT02943785	VKA vs. edoxaban (both with APT if needed)	Patients with atrial fibrillation	1,400	2020	–
ADAPT-TAVR NCT03284827	Edoxaban vs. ASA + clopidogrel (min. 6 months)	Patients without absolute indication for chronic OAC	220	2020	–

APT, antiplatelet therapy; ASA, acetylsalicylic acid; DAPT, double antiplatelet therapy; FU, follow-up; MACE, major adverse cardiovascular events; OAC, oral anticoagulant; SAPT, single antiplatelet therapy; TIA, transient ischemic attack; VKA, vitamin-K antagonist.